Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Durogesic DTrans 50 micrograms/hour Transdermal Patch
Medicines register · Ireland

Durogesic DTrans 50 micrograms/hour Transdermal Patch

Authorisation PA22612/004/002 · Janssen Sciences Ireland Unlimited Company

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 18 Nov 2026
Licence holder
Janssen Sciences Ireland Unlimited Company (all products →)
Active substance
Fentanyl
Clinical trials
31 clinical trials →
Dosage form
Transdermal patch
Route of administration
Transdermal use
ATC codes
N02AB, N02AB03
First authorised
31/10/1995
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Fentanyl: supply and approvals

51 authorised products on the HPRA list contain Fentanyl. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 17 Nov 2026)
US shortage (FDA)
Fentanyl Citrate Injection: in shortage, updated 9 Nov 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 17 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 31 years (since 31 October 1995). The HPRA list marks it as marketed in Ireland.

Other medicines with Fentanyl in Ireland

34 other products on the HPRA list contain Fentanyl, from 8 licence holders; 28 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Abstral 100 microgram sublingual tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Abstral 200 microgram sublingual tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Abstral 300 microgram sublingual tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Abstral 400 microgram sublingual tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Abstral 600 microgram sublingual tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Abstral 800 microgram sublingual tabletsGrunenthal Pharma Limited.National authorisation (PA)Marketed
Actiq 200 micrograms compressed lozenge with integral oromucosal applicatorPhoenix Labs Unlimited CompanyNational authorisation (PA)Marketed
Actiq 400 micrograms compressed lozenge with integral oromucosal applicatorPhoenix Labs Unlimited CompanyNational authorisation (PA)Marketed
Actiq 600 micrograms compressed lozenge with integral oromucosal applicatorPhoenix Labs Unlimited CompanyNational authorisation (PA)Marketed
Durogesic DTrans 100 micrograms/hour transdermal patchJanssen Sciences Ireland Unlimited CompanyNational authorisation (PA)Marketed
Durogesic DTrans 12 micrograms/hour Transdermal PatchJanssen Sciences Ireland Unlimited CompanyNational authorisation (PA)Marketed
Durogesic DTrans 25 micrograms/hour transdermal patchJanssen Sciences Ireland Unlimited CompanyNational authorisation (PA)Marketed

All 35 products with Fentanyl →

Other substances in ATC group N02AB

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 3 other active substances share the group N02AB with this product:

FENTANYL CITRATE (11) · Fentanyl, as citrate salt (2) · Pethidine hydrochloride (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Janssen Sciences Ireland Unlimited Company holds 27 products on the HPRA list, with 6 different active substances; 25 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 18 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.